Sarepta Therapeutics Inc. (SRPT)
Sarepta Therapeutics Inc. (SRPT) Stock Price, Analysis & Data
| Bid | 12.99 |
| Market Cap | 1.94B |
| Revenue (ttm) | 1.97B |
| Net Income (ttm) | -136.72M |
| Beta | 0.20 |
| EPS (ttm) | -1.57 |
| PE Ratio (ttm) | n/a |
| Forward PE | 7.08 |
| P/B (ttm) | 1.27 |
| P/S (ttm) | 0.98 |
| Earnings Date | Nov 4, 2026 |
| Ask | 23.11 |
| Volume | 2,300,996 |
| Avg. Volume (20D) | 3,390,590 |
| Open | 18.06 |
| Previous Close | 18.22 |
| Day's Range | 17.86 - 18.48 |
| 52-Week Range | 14.68 - 25.32 |
| Analyst | Hold |
| Price Target | 20 (8.81%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About SRPT
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in ...
Financial Performance
In 2025, Sarepta Therapeutics's revenue was 2.2B, an increase of 15.58% compared to the previous year's 1.9B. Earnings were -713.41M, a decrease of -403.27%.
Financial StatementsAnalyst Forecast
According to 23 analyst ratings, the average rating for SRPT stock is "Hold". The 12-month stock price forecast is 20, which is upside of 8.81% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
